Neuroimmune cross-talk in heart failure
Cardiovascular Research · 06.05.2025 · 121 (4) · 550-567
DOI: 10.1093/cvr/cvae236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 05.11.2024. Verfasst von Sabrina Montuoro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Piazza Martiri della Libertà, 33, 56127 Pisa, Italy. Hauptthemen laut MEDLINE: Heart Failure, Neuroimmunomodulation, Inflammation Mediators, Autonomic Nervous System. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 219 Literaturangaben. Gefördert von: BioElectronic Approaches in Medicine, Biorobotics Research and Innovation Engineering Facilities, Italian Ministry of Universities and Research.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is characterized by autonomic nervous system (ANS) imbalance and low-grade chronic inflammation. The bidirectional relationship between the ANS and immune system (IS) is named ‘neuroimmune cross-talk’ (NICT) and is based on common signaling molecules, receptors, and pathways. NICT may be altered in HF, and neuroinflammation seems to be a main driver of HF progression. In HF, heightened sympathetic nerve activity triggers inflammatory cascades that lead to cardiomyocyte death and myocardial interstitial fibrosis. Concurrently, parasympathetic withdrawal may impair the cholinergic anti-inflammatory pathway, with a less effective immune response to infections or inflammatory events. Additionally, microglial activation and inflammatory molecules contribute to autonomic imbalance by acting on central nuclei and peripheral visceral feedbacks, which in turn promote adverse cardiac remodeling, HF decompensation, and potentially life-threatening arrhythmias. Therefore, neuroinflammation has been identified as a potential target for treatment. Pharmacological antagonism of the neurohormonal system remains the cornerstone of chronic HF therapy. While some drugs used in HF management may have additional benefits due to their anti-inflammatory properties, clinical trials targeting inflammation in patients with HF have so far produced inconclusive results. Nevertheless, considering the pathophysiological relevance of NICT, its modulation seems an appealing strategy to optimize HF management. Current research is therefore investigating novel pharmacological targets for anti-inflammatory drugs, and the immunomodulatory properties of denervation approaches and bioelectronic medicine devices targeting NICT and neuroinflammation in HF. A deeper understanding of the complex relationship between the ANS and IS, as outlined in this review, could therefore facilitate the design of future studies aimed at improving outcomes by targeting NICT in patients with HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Piazza Martiri della Libertà, 33, 56127 Pisa, Italy.
- Cardiovascular Medicine Division, Fondazione Toscana G. Monasterio, Via Moruzzi 1, 56126 Pisa, Italy.
ORCID-Profile: Francesco Gentile
Förderung
- BioElectronic Approaches in Medicine
- Biorobotics Research and Innovation Engineering Facilities
- Italian Ministry of Universities and Research
Zitieren
APA
Montuoro, S., Gentile, F., & Giannoni, A. (2025). Neuroimmune cross-talk in heart failure. Cardiovascular Research, 121(4), 550-567. https://doi.org/10.1093/cvr/cvae236
Vancouver
Montuoro S, Gentile F, Giannoni A. Neuroimmune cross-talk in heart failure. Cardiovascular Research. 2025;121(4):550-567. doi:10.1093/cvr/cvae236
BibTeX
@article{Montuoro2025,
author = {Montuoro, Sabrina and Gentile, Francesco and Giannoni, Alberto},
title = {Neuroimmune cross-talk in heart failure},
journal = {Cardiovascular Research},
year = {2025},
volume = {121},
number = {4},
pages = {550--567},
doi = {10.1093/cvr/cvae236}
}
EUVIMED